Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015

Aratana Therapeutics, Inc. PETX, a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today provided commentary on clinical study data involving ADXS31-164 (AT-014) that was recently presented during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2015. ADXS31-164 is a novel Lm-LLO immunotherapy developed by Advaxis, Inc. ADXS to target HER2 receptor expressing cancers.  In March 2014, Aratana licensed ADXS31-164 from Advaxis for the treatment of canine osteosarcoma and other cancers, adding the drug product to its pipeline of cancer therapeutics as AT-014. On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma (Poster Board #7; Abstract #LB-113).  The data suggests that ADXS31-164 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for See full press release